144 related articles for article (PubMed ID: 31355317)
1. Trial of canakinumab, an IL-1β receptor antagonist, in patients with inclusion body myositis.
Kosmidis ML; Pikazis D; Vlachoyiannopoulos P; Tzioufas AG; Dalakas MC
Neurol Neuroimmunol Neuroinflamm; 2019 Jul; 6(4):e581. PubMed ID: 31355317
[TBL] [Abstract][Full Text] [Related]
2. Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis.
Dalakas MC; Rakocevic G; Schmidt J; Salajegheh M; McElroy B; Harris-Love MO; Shrader JA; Levy EW; Dambrosia J; Kampen RL; Bruno DA; Kirk AD
Brain; 2009 Jun; 132(Pt 6):1536-44. PubMed ID: 19454532
[TBL] [Abstract][Full Text] [Related]
3. The effect of anakinra, an IL1 receptor antagonist, in patients with sporadic inclusion body myositis (sIBM): a small pilot study.
Kosmidis ML; Alexopoulos H; Tzioufas AG; Dalakas MC
J Neurol Sci; 2013 Nov; 334(1-2):123-5. PubMed ID: 23998706
[TBL] [Abstract][Full Text] [Related]
4. Sustained efficacy of the monoclonal anti-interleukin-1 beta antibody canakinumab in a 9-month trial in Schnitzler's syndrome.
de Koning HD; Schalkwijk J; van der Ven-Jongekrijg J; Stoffels M; van der Meer JW; Simon A
Ann Rheum Dis; 2013 Oct; 72(10):1634-8. PubMed ID: 23087179
[TBL] [Abstract][Full Text] [Related]
5. Long-term safety and tolerability of bimagrumab (BYM338) in sporadic inclusion body myositis.
Sivakumar K; Cochrane TI; Sloth B; Ashar H; Laurent D; Tankó LB; Amato AA
Neurology; 2020 Oct; 95(14):e1971-e1978. PubMed ID: 32690797
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Bimagrumab in Sporadic Inclusion Body Myositis: Long-term Extension of RESILIENT.
Amato AA; Hanna MG; Machado PM; Badrising UA; Chinoy H; Benveniste O; Karanam AK; Wu M; Tankó LB; Schubert-Tennigkeit AA; Papanicolaou DA; Lloyd TE; Needham M; Liang C; Reardon KA; de Visser M; Ascherman DP; Barohn RJ; Dimachkie MM; Miller JAL; Kissel JT; Oskarsson B; Joyce NC; Van den Bergh P; Baets J; De Bleecker JL; Karam C; David WS; Mirabella M; Nations SP; Jung HH; Pegoraro E; Maggi L; Rodolico C; Filosto M; Shaibani AI; Sivakumar K; Goyal NA; Mori-Yoshimura M; Yamashita S; Suzuki N; Aoki M; Katsuno M; Morihata H; Murata K; Nodera H; Nishino I; Romano CD; Williams VSL; Vissing J; Zhang Auberson L;
Neurology; 2021 Mar; 96(12):e1595-e1607. PubMed ID: 33597289
[TBL] [Abstract][Full Text] [Related]
7. Treatment of sporadic inclusion body myositis with bimagrumab.
Amato AA; Sivakumar K; Goyal N; David WS; Salajegheh M; Praestgaard J; Lach-Trifilieff E; Trendelenburg AU; Laurent D; Glass DJ; Roubenoff R; Tseng BS; Greenberg SA
Neurology; 2014 Dec; 83(24):2239-46. PubMed ID: 25381300
[TBL] [Abstract][Full Text] [Related]
8. Long-term follow-up of sporadic inclusion body myositis treated with intravenous immunoglobulin: a retrospective study of 16 patients.
Dobloug C; Walle-Hansen R; Gran JT; Molberg Ø
Clin Exp Rheumatol; 2012; 30(6):838-42. PubMed ID: 22935197
[TBL] [Abstract][Full Text] [Related]
9. Selective activation of pro-anti-IL-1β antibody enhances specificity for autoinflammatory disorder therapy.
Lin WW; Lu YC; Huang BC; Chuang CH; Cheng YA; Chen IJ; Liu HJ; Ho KW; Liao TY; Liu ES; Wu TY; Chang LS; Hong ST; Cheng TL
Sci Rep; 2021 Jul; 11(1):14846. PubMed ID: 34290297
[TBL] [Abstract][Full Text] [Related]
10. Effects of Interleukin-1β Inhibition on Incident Anemia: Exploratory Analyses From a Randomized Trial.
Vallurupalli M; MacFadyen JG; Glynn RJ; Thuren T; Libby P; Berliner N; Ridker PM
Ann Intern Med; 2020 Apr; 172(8):523-532. PubMed ID: 32203978
[TBL] [Abstract][Full Text] [Related]
11. Arterial Effects of Canakinumab in Patients With Atherosclerosis and Type 2 Diabetes or Glucose Intolerance.
Choudhury RP; Birks JS; Mani V; Biasiolli L; Robson MD; L'Allier PL; Gingras MA; Alie N; McLaughlin MA; Basson CT; Schecter AD; Svensson EC; Zhang Y; Yates D; Tardif JC; Fayad ZA
J Am Coll Cardiol; 2016 Oct; 68(16):1769-1780. PubMed ID: 27737744
[TBL] [Abstract][Full Text] [Related]
12. One target-two different binding modes: structural insights into gevokizumab and canakinumab interactions to interleukin-1β.
Blech M; Peter D; Fischer P; Bauer MM; Hafner M; Zeeb M; Nar H
J Mol Biol; 2013 Jan; 425(1):94-111. PubMed ID: 23041424
[TBL] [Abstract][Full Text] [Related]
13. Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS).
Ridker PM; Libby P; MacFadyen JG; Thuren T; Ballantyne C; Fonseca F; Koenig W; Shimokawa H; Everett BM; Glynn RJ
Eur Heart J; 2018 Oct; 39(38):3499-3507. PubMed ID: 30165610
[TBL] [Abstract][Full Text] [Related]
14. The long and winding road in pharmaceutical development of canakinumab from rare genetic autoinflammatory syndromes to myocardial infarction and cancer.
Gram H
Pharmacol Res; 2020 Apr; 154():104139. PubMed ID: 30648616
[TBL] [Abstract][Full Text] [Related]
15. Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes.
Everett BM; Donath MY; Pradhan AD; Thuren T; Pais P; Nicolau JC; Glynn RJ; Libby P; Ridker PM
J Am Coll Cardiol; 2018 May; 71(21):2392-2401. PubMed ID: 29544870
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of Interleukin-1β and Reduction in Atherothrombotic Cardiovascular Events in the CANTOS Trial.
Everett BM; MacFadyen JG; Thuren T; Libby P; Glynn RJ; Ridker PM
J Am Coll Cardiol; 2020 Oct; 76(14):1660-1670. PubMed ID: 33004131
[TBL] [Abstract][Full Text] [Related]
17. Effect of anti-IL-1β antibody (canakinumab) on insulin secretion rates in impaired glucose tolerance or type 2 diabetes: results of a randomized, placebo-controlled trial.
Rissanen A; Howard CP; Botha J; Thuren T;
Diabetes Obes Metab; 2012 Dec; 14(12):1088-96. PubMed ID: 22726220
[TBL] [Abstract][Full Text] [Related]
18. Sporadic inclusion body myositis: clinical, pathological, and genetic analysis of eight Polish patients.
Kierdaszuk B; Berdynski M; Palczewski P; Golebiowski M; Zekanowski C; Kaminska AM
Folia Neuropathol; 2015; 53(4):355-66. PubMed ID: 26785370
[TBL] [Abstract][Full Text] [Related]
19. Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes.
Kuemmerle-Deschner JB; Hachulla E; Cartwright R; Hawkins PN; Tran TA; Bader-Meunier B; Hoyer J; Gattorno M; Gul A; Smith J; Leslie KS; Jiménez S; Morell-Dubois S; Davis N; Patel N; Widmer A; Preiss R; Lachmann HJ
Ann Rheum Dis; 2011 Dec; 70(12):2095-102. PubMed ID: 21859692
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of Interleukin-1β by Canakinumab and Cardiovascular Outcomes in Patients With Chronic Kidney Disease.
Ridker PM; MacFadyen JG; Glynn RJ; Koenig W; Libby P; Everett BM; Lefkowitz M; Thuren T; Cornel JH
J Am Coll Cardiol; 2018 May; 71(21):2405-2414. PubMed ID: 29793629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
